Tuesday, July 26, 2011
Monday, July 25, 2011
Sunday, July 24, 2011
Friday, July 22, 2011
Thursday, July 21, 2011
FDA approves AstraZeneca's anti-clotting drug Brilinta
In continuation of my update on Ticagrelor (Brilinta)......
FDA approves AstraZeneca's anti-clotting drug Brilinta
Labels:
anticlotting,
Ticagrelor (Brilinta)
Wednesday, July 20, 2011
Sunday, July 17, 2011
Tocotrienol could help reduce stroke damage
In continuation of my update on the benefits of Vitamin E
Tocotrienol could help reduce stroke damage
Saturday, July 16, 2011
Grape seed polyphenols may help prevent Alzheimer's disease
In continuation of my update on the usefulness of polyphenols....
Grape polyphenols are also called Vineatrols (see structure : vineatrol / trans-resveratrol)
Tuesday, July 12, 2011
Telaprevir drug shows promise in curing hepatitis C infection
In continuation of my update on Telaprevir...............
Labels:
Hepatitis C,
Incivek (Telaprevir)
Monday, July 11, 2011
Sunday, July 10, 2011
FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis
We know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....
Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....
More....
Saturday, July 9, 2011
Sulforaphane-rich foods safe and effective for preventing cancer
In continuation of my update on the benefits of broccoli and sulforaphane............
Labels:
anticancer activity,
broccoli,
sulforaphane
Thursday, July 7, 2011
New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease
We know that Bardoxolone methyl (see the structure, also known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......
Labels:
Bardoxolone methyl,
diabetes type 2function,
kidney
Wednesday, July 6, 2011
Subscribe to:
Posts (Atom)